BigHat Biosciences discloses Series C filing with SEC
The San Mateo biotechnology company reported $75.1 million sold toward an offering that could raise up to $80 million, per a Form D filed October 26, 2026.
BigHat Biosciences, Inc. filed a Form D with the Securities and Exchange Commission on October 26, 2026, disclosing details of a securities offering. The total offering amount is listed as $79,999,947, with $75,141,086 already sold and $4,858,861 remaining to be sold.1 The filing clarifies that the securities involved are Series C Preferred Stock and the Common Stock issuable upon conversion thereof.1
The company is incorporated in Delaware and was formed over five years ago1. Its principal place of business is listed at 1900 Alameda de las Pulgas, Suite 400, San Mateo, California 94403.1
The filing names several related persons. Peyton Greenside is listed as both an executive officer and director, while Vineeta Agarwala, Robert Chess, Francisco Gimenez, and Andrew Conrad are each listed as directors.1
According to the filing, this is a new notice with a date of first sale of July 17, 2026.1 The company indicated it does not intend the offering to last more than one year.1 The filing states that 29 investors have already invested in the offering.1
The company classified itself under the Biotechnology1 industry group within Health Care. It claimed an exemption under Rule 506(b)1 of Regulation D. The filing reports $0 in sales commissions and finders' fees1 and $0 in proceeds allocated to payments for executive officers, directors, or promoters named in the filing.1
The Form D was signed by Peyton Greenside, Chief Executive Officer, on October 26, 2026.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.